Related references
Note: Only part of the references are listed.Effect of the Novel Thienopyridine Prasugrel Compared With Clopidogrel on Spontaneous and Procedural Myocardial Infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38 An Application of the Classification System From the Universal Definition of Myocardial Infarction
David A. Morrow et al.
CIRCULATION (2009)
Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel Relationship to Pharmacokinetic, Pharmacodynamic, and Clinical Outcomes
Jessica L. Mega et al.
CIRCULATION (2009)
Effect of Age on the Pharmacokinetics and Pharmacodynamics of Prasugrel during Multiple Dosing An Open-Label, Single-Sequence, Clinical Trial
David S. Small et al.
DRUGS & AGING (2009)
Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention
Dirk Sibbing et al.
EUROPEAN HEART JOURNAL (2009)
Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy
Alan R. Shuldiner et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Population Pharmacokinetic Analyses to Evaluate the Influence of Intrinsic and Extrinsic Factors on Exposure of Prasugrel Active Metabolite in TRITON-TIMI 38
Rebecca E. Wrishko et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Pharmacokinetics and pharmacodynamics of prasugrel in subjects with moderate liver disease
D. S. Small et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2009)
Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease
D. S. Small et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2009)
Role of Clopidogrel Loading Dose in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Angioplasty Results From the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial
George Dangas et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
The Efficacy and Safety of Prasugrel With and Without a Glycoprotein IIb/IIIa Inhibitor in Patients With Acute Coronary Syndromes Undergoing Percutaneous Intervention A TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) Analysis
Michelle O'Donoghue et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials
Michelle L. O'Donoghue et al.
LANCET (2009)
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial
Gilles Montalescot et al.
LANCET (2009)
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study
Jean-Philippe Collet et al.
LANCET (2009)
Geographic Atrophy in Age-Related Macular Degeneration andTLR3
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Weighing Benefits and Risks -- The FDA's Review of Prasugrel.
Ellis F. Unger
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
Lars Wallentin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Genetic Determinants of Response to Clopidogrel and Cardiovascular Events.
Tabassome Simon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Mechanisms of platelet activation: Need for new strategies to protect against platelet-mediated atherothrombosis
Lisa K. Jennings
THROMBOSIS AND HAEMOSTASIS (2009)
A perspective on the efficacy and safety of intensive antiplatelet therapy in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-thrombolysis in myocardial infarction 38
Stephen D. Wiviott et al.
AMERICAN JOURNAL OF CARDIOLOGY (2008)
Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38
Stephen D. Wiviott et al.
CIRCULATION (2008)
2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction - A report of the American college of cardiology/American heart association task force on practice guidelines
Elliott M. Antman et al.
CIRCULATION (2008)
Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial
Stephen D. Wiviott et al.
LANCET (2008)
Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention - The prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial
Stephen D. Wiviott et al.
CIRCULATION (2007)
Prasugrel: A novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile
Joseph A. Jakubowski et al.
CARDIOVASCULAR DRUG REVIEWS (2007)
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Stephen D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Meta-analysis appraising high Clopidogrel loading in patients undergoing percutaneous coronary interventiont
Marzia Lotrionte et al.
AMERICAN JOURNAL OF CARDIOLOGY (2007)
The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite
A. Sugidachi et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
The disposition of prasugrel, a novel thienopyridine, in humans
Nagy A. Farid et al.
DRUG METABOLISM AND DISPOSITION (2007)
Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis
Piergiovanni Buonamici et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently
N. A. Farid et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation
John T. Brandt et al.
AMERICAN HEART JOURNAL (2007)
Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement
Willibald Hochholzer et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38)
Stephen D. Wiviott et al.
AMERICAN HEART JOURNAL (2006)
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease
T Jernberg et al.
EUROPEAN HEART JOURNAL (2006)
ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention)
SC Smith et al.
CIRCULATION (2006)
ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention - Summary Article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention)
SC Smith et al.
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS (2006)
Clopidogrel effect on platelet REactivity in patients with stent thrombosis - Results of the CREST study
PA Gurbel et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial
ZM Chen et al.
LANCET (2005)
Randomized comparison of Prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention -: Results of the joint utilization of medications to block platelets optimally (JUMBO)-TIMI 26 trial
SD Wiviott et al.
CIRCULATION (2005)
Stent thrombosis is associated with an impaired response to antiplatelet therapy
P Wenaweser et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention - Results from the ARMYDA-2 (Antiplatelet therapy for reduction of MYocardial Damage during Angioplasty) study
G Patti et al.
CIRCULATION (2005)
Guidelines for percutaneous coronary interventions -: The task force for percutaneous coronary interventions of the European Society of Cardiology
S Silber et al.
EUROPEAN HEART JOURNAL (2005)
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation
MS Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-2002: Summary article - A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina)
E Braunwald et al.
CIRCULATION (2002)
The P2Y12 receptor as a therapeutic target in cardiovascular disease
RF Storey
PLATELETS (2001)